Clazakizumab
Clazakizumab has been studied in 3 papers since 2026: none in people yet, 2 reviews; 3 in the past year. No study of it in people or animals has been published yet. The newest paper, Aug 25, 2026: “Targeting Inflammation in Chronic Kidney Disease: Pathophysiological Insights and Emerging Therapeutic Strategies”.
3 papers study it1 findingUpdated
See all 3 papers on clazakizumab
At a glance
4 trials, none about aging.
Cells, worms or flies, mice and humans: nothing yet.
- 4 trials, none about aging
- 3 of 4 trials sponsored by its developers
What did studies of clazakizumab find?
1Studies of clazakizumab measured one outcome, inflammatory biomarkers.
Inflammatory biomarkers
downin humans1
1 study
Inflammatory biomarkers
downin humans1
Clazakizumab decreases inflammatory biomarkers in humans.
Review
Who is developing clazakizumab?
2 companies: CSL Behring and Eli Lilly.
Trial sponsors
Company1 trialPhase 2/33,110 people
Company1 trialPhase 2120 people
Latest
3 papers in 12 monthsJournal of the American Geriatrics Society
The "Reducing Inflammation for Greater Health Trial (RIGHT)" Study-Concept, Rationale, and Design
Study protocolInterventions